ERBB2 and breast carcinoma: T-DM1, one of the ADCs approved for patients with HER2-positive breast cancer, is conjugated to trastuzumab via a non-cleavable thioether linker, and the payload has a low level of cell permeability; therefore, the bystander effect is not observed in this case [39].